Good manufacturing practice-compliant isolation and culture of human umbilical cord blood-derived mesenchymal stem cells

Phuc Van Pham*, Ngoc Bich Vu, Vuong Minh Pham, Nhung Hai Truong, Truc Le-Buu Pham, Loan Thi-Tung Dang, Tam Thanh Nguyen, Anh Nguyen-Tu Bui and Ngoc Kim Phan

Abstract

Background: Mesenchymal stem cells (MSCs) are an attractive source of stem cells for clinical applications. These cells exhibit a multilineage differentiation potential and strong capacity for immune modulation. Thus, MSCs are widely used in cell therapy, tissue engineering, and immunotherapy. Because of important advantages, umbilical cord blood-derived MSCs (UCB-MSCs) have attracted interest for some time. However, the applications of UCB-MSCs are limited by the small number of recoverable UCB-MSCs and fetal bovine serum (FBS)-dependent expansion methods. Hence, this study aimed to establish a xenogenic and allogeneic supplement-free expansion protocol.

Methods: UCB was collected to prepare activated platelet-rich plasma (aPRP) and mononuclear cells (MNCs). aPRP was applied as a supplement in Iscove modified Dulbecco medium (IMDM) together with antibiotics. MNCs were cultured in complete IMDM with four concentrations of aPRP (2, 5, 7, or 10%) or 10% FBS as the control. The efficiency of the protocols was evaluated in terms of the number of adherent cells and their expansion, the percentage of successfully isolated cells in the primary culture, surface marker expression, and in vitro differentiation potential following expansion.

Results: The results showed that primary cultures with complete medium containing 10% aPRP exhibited the highest success, whereas expansion in complete medium containing 5% aPRP was suitable. UCB-MSCs isolated using this protocol maintained their immunophenotypes, multilineage differentiation potential, and did not form tumors when injected at a high dose into athymic nude mice.

Conclusion: This technique provides a method to obtain UCB-MSCs compliant with good manufacturing practices for clinical application.

Keywords: Mesenchymal stem cells, Platelet-rich plasma, Umbilical cord blood, Good manufacturing practice, Clinical application

Introduction

Mesenchymal stem cells (MSCs) are one of the most studied and applied types of stem cells to date. These cells were first described by Friedenstein et al. as a cell population similar to fibroblasts [1], which can differentiate into multiple cell types such as osteoblasts, adipocytes, and chondrocytes [2]. MSCs have been isolated from many tissues including bone marrow [3,4], adipose tissue [5-7], peripheral blood, umbilical cord blood (UCB) [8-10], banked UCB [11-14], umbilical cords [15,16], placenta [17], amniotic fluid [18], dental pulp [19], and menstrual blood [20].

Compared with other stem cell sources, UCB-MSCs have advantages such as non-invasive recovery, the abundance of MSCs, and well-known characteristics. In both pre-clinical and clinical settings, MSCs have been studied to treat a various diseases. Pre-clinically, UCB-MSCs have been used to treat neonatal brain injury [21], fibrocartilaginous embolic myelopathy [22], spinal cord...
injury [23,24], diabetic renal injury [25,26], bone loss [27], ischemia [28,29], hearing loss [30], damaged corneal endothelium [31], Alzheimer’s disease [32], graft-versus-host disease (GVHD) [33], acute hepatic necrosis [34], diabetes mellitus [35], and liver cirrhosis [36]. Clinically, UCB-MSCs have been transplanted for treatment of autism [37], hereditary spino cerebellar ataxia [38], foot disease in patients with type 2 diabetes mellitus [39], and basilar artery dissection [40]. Clinical trials (retrieved from clinicaltrial.gov) include mesenchymal stem cell transplantation for engraftment of unrelated hematopoietic stem cell transplantation (NCT00823316), treatment of steroid-refractory acute or GVHD (NCT01549665), articular cartilage defect treatment (NCT01733186), and hematologic malignancy treatment (NCT01854567).

The main concern in UCB-MSC applications is in vitro expansion that is mostly affected by the culture medium. For production protocols of UCB-MSCs under clinical conditions, it is essential to include sterility controls, analysis for viral markers, and genetic testing such as karyotyping. Currently, UCB-MSCs can be produced at a GMP (good manufacturing practice) grade by automated processing protocols and some novel protocols. Procedures have been developed to isolate mononuclear cells (MNCs) in closed systems such as the SEPAX device [41,42]. Other systems can also be expanded to expand MSCs such as the Cell Stack System [43]. However, almost all of these methods require fetal bovine serum (FBS) for culture. FBS-based medium has some limitations associated with clinical application, especially prion and viral transmission or adverse immunological reactions against xenogenic components.

Some novel methods use human serum for MSC culture, especially platelet-rich plasma (PRP). Recent studies have used PRP from peripheral blood [44-48] and UCB [49-52], which showed that PRP from peripheral blood or UCB significantly promotes proliferation of MSC from bone marrow [45,50], UCB [49,53], or adipose tissue [44,54]. More importantly, MSCs cultured in medium supplemented with PRP exhibit a normal phenotype and characteristics [49-52], and maintain their multipotency for differentiation into adipocytes, osteoblasts, and chondrocytes. Taken together, these studies show that PRP can replace FBS for in vitro MSC expansion.

All of these previous protocols have used allogeneic PRP. The use of PRP allows MSCs to avoid xenogenic immunological reactions, and prion and viral transmission, but MSCs may encounter human viral transmission and immunological reactions induced by allogeneic components. According to the European Medicines Agency and regulation No. [EC] 1394/2007 of the European Commission, MSC are considered as medicinal products [55] and must be produced in compliance with GMP. The GMP standards ensure that cells are produced with the highest standards of sterility, quality control, and documentation following a standard operating procedure. Therefore, in this study, we aimed to establish an UCB-MSC isolation protocol using autologous PRP from the same umbilical blood sample. This protocol is GMP compliant and can be used for clinical applications.

Materials and methods

UCB collection and sample selection for study

UCB was collected from the umbilical cord vein with informed consent of the mother. The collection was performed in accordance with the ethical standards of the local ethics committee. To eliminate differences between UCB samples, the stem cell quantity was enumerated based on the number of hematopoietic stem cells (HSCs) using an Enumeration Pro-Count Kit (BD Bioscience) following the manufacturer’s guidelines. Only samples with ≥ 1 × 10⁶ HSCs/ml were used in experiments.

MNC isolation and activated PRP preparation

First, blood samples were centrifuged at 2000 rpm for 15 min. The cell pellet was kept to isolate MNCs and the plasma was collected and centrifuged at 3500 rpm for 10 min. To prepare activated PRP (aPRP), a third of the plasma volume and the platelet pellet was collected and resuspended, and then 100 μL CaCl₂ per 1 mL of PRP was added to activate growth factor release. The samples were then incubated at 37°C for 30 min or until the occurrence of clotting. The centrifuged blood cells were diluted at a ratio of 1:1 with phosphate buffered solution (PBS) and then applied to density centrifugation using Ficoll Hypaque (1.077 g/mL; Sigma-Aldrich, St Louis, MO). The collected MNCs were washed twice with PBS and then applied to experiments.

Primary culture

Twenty UCB samples were used for primary culture. MNCs were cultured in Iscove modified Dulbecco medium (IMDM) containing 1% antibiotic-mycotic (Sigma-Aldrich, Louis St, MO), 10 ng/mL epidermal growth factor (EGF), 10 ng/mL basic fibroblast growth factor (bFGF), and various concentrations of aPRP (2, 5, 7, or 10%) or 10% fetal bovine serum (FBS) for the control. The cells were plated at 5 × 10⁵ cells/mL in T-75 flasks (Corning) and incubated at 37°C with 5% CO₂. After 3 days of incubation, 6 mL of fresh media were added to each flask. After 7 days, the media were replaced with fresh media. Then, the media was replaced every 4 days until the cells reached 70–80% confluence. The efficiency of the media was evaluated by the time required for adherent cells to appear and then reach 70–80% confluence for the first subculture.

Secondary culture

After successful primary culture, the samples were subcultured to evaluate the effects of the various media.
The proliferation rate was evaluated by the eXCELLi-gence system (Roche Applied Science, Indianapolis, IN). A total of $1 \times 10^3$ cells were seeded into each well of a 96-well E-plate in triplicate. The culture plates were placed into the eXCELLi-gence system and incubated at 37°C with 5% CO$_2$. Cell proliferation was monitored for 300 h with fresh medium changes every third day. Both the cell doubling time and slope value were determined by the software of the eXCELLi-gence system.

**Flow cytometry**

Cell markers were analyzed following a previously published protocol [11]. Briefly, cells were washed twice in PBS containing 1% bovine serum albumin (Sigma-Aldrich). The cells were then stained with anti-CD13-FITC, anti-CD14-FITC, anti-CD34-FITC, anti-CD44-PE, anti-CD45-FITC, anti-CD73-FITC, anti-CD90-PE, anti-CD105-FITC, anti-CD106-PE, anti-CD166-PE, or anti-HLA-DR-FITC antibodies (all purchased from BD Biosciences, San Jose, CA). Stained cells were analyzed by a FACSCalibur flow cytometer (BD Biosciences). Isotype controls were used in all analyses.

**In vitro differentiation**

For differentiation into adipogenic cells, UCB-MSCs were induced to differentiate by a commercial medium for chondrogenesis (StemPro Chondrogenesis Differentiation Kit, A10071-01; Life Technologies). UCB-MSCs were differentiated in pellet form according to the manufacturer’s guidelines. After 21 days, the cell pellets were stained with an anti-aggrecan monoclonal antibody (BD Biosciences).

**Tumorigenicity assay**

The tumorigenicity of UCB-MSCs was examined in athymic nude mice. All manipulations of mice were approved by the Local Ethics Committee of Stem Cell Research and Application, University of Science (Ho Chi Minh city, Vietnam). Each mouse was injected subcutaneously with $5 \times 10^6$ cells (three mice per group). As a positive control, the mice were also injected with breast cancer cells at a different site. Tumor formation in mice was followed up for 3 months.

**Statistical analysis**

The significance of differences between mean values was assessed by t-tests and analysis of variance. A P-value of less than 0.05 was considered to be significant. All data were analyzed by Prism 6 software.

**Results**

**Primary cell culture**

We collected 30 UCB samples of which 20 were applied to experiments. For primary culture, MNCs from the same sample were divided and cultured in five different media containing 10% FBS or 2, 5, 7, or 10% aPRP. There were differences in the time needed for MNCs to adhere and exhibit a particular shape in the various media. For example, at 72 h post-plating, there were clear differences in the number of adhered and fibroblast-like cells (Figure 1).

As shown in Figure 2A, fibroblast-like cells appeared the most rapidly in 10% aPRP (46.20 ± 8.94 h), which
was significantly sooner than that in 7% aPRP (52.80 ± 10.59 h), 5% aPRP (60.60 ± 10.64 h), 2% aPRP (61.80 ± 10.50 h), and 10% FBS (52.80 ± 12.56 h). These results showed that increases of the aPRP concentration led to decreases in the time needed for MNCs to adhere and exhibit a fibroblastic shape, indicating that components of aPRP were important for adherence and proliferation of UCB-MSCs.

These times also dictated the number of days until the first subculture (Figure 2B). As a result, 70–80% confluence was reached at 23.35 ± 4.73 days in 10% aPRP, whereas 25.50 ± 4.62, 30.40 ± 5.05, 30.40 ± 5.05, and 26.55 ± 7.05 days were required in 7, 5, or 2% aPRP, or 10% FBS, respectively.

**Cell proliferation rates in the various media**

After subculture, five samples were used to evaluate the effects of the various media on UCB-MSC proliferation. The results are presented in Figure 3. The proliferation rates of the cells in the various media were recorded from 0 to 300 h. At 0–130 h, the proliferation rates among the media were not significantly different. However, from 130 to 260 h, the proliferation rates were significantly different in 5, 7, or 10% aPRP, or 10% FBS compared with that in 2% aPRP. From 260 to 300 h, cells in all the various media underwent contact inhibition and death. As shown in Figure 3, the proliferation rate of cells in 10% aPRP was higher than that in the other media but the difference was not significant.

We also compared the cell doubling times and slope values (Figure 4). The doubling time is the time needed for the cell population to double in number. There were no differences in the doubling times for the whole period from 0 to 300 h. However, there were significant changes at each period from 0 to 130 h and 130 to 260 h. In the early stage (0–130 h), the doubling times were similar between the media (24.9 ± 6.11, 22.6 ± 4.9, 28.1 ± 5.71, 27.6 ± 5.52, and 25.5 ± 6.48 h in 10% FBS or 2, 5, 7, or 10% aPRP, respectively) (P < 0.05). In the next period (from 130 to 260 h), cells in all the various media proliferated with increasing doubling times. At this stage, the doubling times were similar in 5, 7, or 10% aPRP (P < 0.05) (131 ± 2.51, 134 ± 3, and 134 ± 2.49 h in 5, 7, or 10% aPRP, respectively). In contrast, the doubling time in 2% aPRP suddenly increased to 148 ± 3.63 h. In 10% FBS, the doubling time was 139 ± 2.82 h which was lower than that in 2% aPRP but higher than that in 5, 7, or 10% aPRP, but the difference was not significant.

These data further confirmed that the proliferation rate of UCB-MSCs in 5, 7, or 10% aPRP were similar to that in 10% FBS, but higher than that in 2% aPRP. The slope values also supported these results. In the early stage (0–130 h), there were no differences in the slope values among the media (0.021 ± 0.001, 0.018 ± 0.001, 0.020 ± 0.001, 0.021 ± 0.001, and 0.021 ± 0.001 for 10% FBS or 2, 5, 7, or 10% aPRP, respectively). In the next stage (130–260 h), the slope values exhibited significant differences between 10% FBS or 5, 7, or 10% aPRP.
Figure 4 Doubling times and slope values in the various media. The values were obtained at three stages, 0–130 h, 130–260 h, and 260–300 h, and the whole proliferation curve at 0–300 h. There were no significant differences between the doubling times (A) and slope values (B) in 5, 7, or 10% aPRP, or 10% FBS, but a significant difference in 2% aPRP.

Figure 5 Immunophenotypes of MSCs in the various media. The results include flow cytometric analysis of CD13, CD14, CD34, CD44, CD45, CD73, CD90, CD105, CD106, CD166, and HLA-DR (A). Data were analyzed and presented in a graph (B).
(0.023 ± 0.001, 0.023 ± 0.001, 0.023 ± 0.001, and 0.024 ± 0.001, respectively) compared with that in 2% aPRP.

**Phenotypes of MSCs**

MSC-specific marker expression of UCB-MSCs cultured in the various media were evaluated and compared as presented in Figure 5. The results showed that UCB-MSCs in all the media exhibited a MSC-specific marker profile, positivity for CD13, CD44, CD73, CD90, CD105, CD106, and CD166, and negativity for CD14, CD34, CD45, and HLA-DR. The expression levels of positive markers in MSCs were similar among the media.

UCB-MSCs cultured in the various media were examined for their capacity to differentiate into adipogenic, osteogenic, and chondrogenic lineages. The results of differentiation assays are presented in Figures 6 and 7. In all media, the cells successfully differentiated into adipocytes, osteoblasts, and chondrocytes. Compared with cells prior to induction (Figure 6A–E), cells in all media accumulated lipid droplets in their cytoplasm after induction with adipocyte differentiation medium (Figure 6F–K).

Following induction with osteoblast differentiation medium, cells in all media accumulated Ca\(^{2+}\) and Mg\(^{2+}\) in the cytoplasm and extracellular matrix, which were stained with Alizarin red (Figure 6I–P). After 21 days of chondrogenic differentiation, cells in all media expressed aggrecan, a cartilage-specific proteoglycan core protein (Figure 7).

**Tumorigenicity of UCB-MSCs**

UCB-MSCs cultured in the various media were injected into athymic nude mice. Breast cancer cells were also injected at a different location as a positive control. Injection of UCB-MSCs resulted in no tumor formation, whereas injection of breast cancer cells resulted in tumor formation in all mice (Figure 8).

**Discussion**

The aim of this study was to establish a GMP-compliant protocol for isolation of UCB-MSC for clinical application. Therefore, we eliminated xenogenic and allogeneic components that can cause immunological reactions and viral transmission. Our approach replaced FBS in the medium with autologous aPRP that was isolated from the same UCB sample used to isolate MNCs.

Because the source of autologous aPRP was limited and the necessary number of MSCs for clinical application is high, we evaluated four concentrations of aPRP in complete medium, including 2, 5, 7, and 10%, and 10% FBS as a control. The effects of aPRP on MSC proliferation was evaluated in primary and secondary cultures. In primary culture, medium containing 10% aPRP significantly stimulated MSC proliferation compared with that of the other aPRP concentrations and 10% FBS. In medium containing 10% aPRP, MSCs adhered quickly and proliferated rapidly. These observations demonstrated that aPRP contains all the essential components similar to those in FBS for support of cell attachment and proliferation. In fact, aPRP contains high amounts of attachment proteins such as fibrin, fibronectin, vitronectin, and thrombospondin [49,56]. In addition, aPRP contains several growth factors that stimulate cell proliferation, such as EGF, acidic fibroblast growth factor, keratinocyte growth factor,
vascular endothelial growth factor, platelet-derived growth factor, hepatocyte growth factor, and bFGF [49,52,57]. Compared with bovine growth factors in FBS, aPRP can be obtained from humans, allowing better interactions between growth factors and cell receptors. In primary culture, the time needed to reach confluency in 10% aPRP indicated that this concentration of aPRP induced stronger MSC proliferation than that of FBS.

In expansion culture, the effects of the four concentrations of aPRP were also evaluated alongside the 10% FBS control. The results showed that there were no differences between 5, 7, or 10% aPRP supplementation compared with 10% FBS, but these aPRP concentrations showed significantly different effects than those of 2% aPRP. In fact, we confirmed these effects by the proliferation curve, doubling time, and slope value for proliferation. Based on proliferation curves, we could easily recognize differences in the proliferation rates between 2% aPRP and the other aPRP concentrations. However, the proliferation rates in 5, 7, or 10% aPRP or 10% FBS were not increased significantly. These data indicated the differences in the growth factor concentrations at 5, 7 and 10% aPRP did not cause

**Figure 7** MSCs cultured in the various media can differentiate into chondrocytes. Differentiated cells (A, E, I, R, and N are 10% FBS or 2, 5, 7, or 10% aPRP, respectively) were stained with Hoescht 33342. B, F, K, O, and S are 10% FBS or 2, 5, 7, or 10% aPRP, respectively and an anti-aggreCan monoclonal antibody. (C, G, L, P and T are 10% FBS or 2, 5, 7, or 10% aPRP, respectively). Merged images with brightfield as shown in D, H, M, Q, and U for 10% FBS or 2, 5, 7, or 10% aPRP, respectively.
any significant difference in the proliferation of UCB-MSCs.

Other important properties that we evaluated were the effects of aPRP-containing medium on surface marker expression and multilineage differentiation of UCB-MSCs. We used the marker profile of positive and negative markers suggested by Domicini et al. [58]. The results showed that UCB-MSCs maintained their marker expression in aPRP-containing media compared with that in medium supplemented with FBS. UCB-MSCs cultured in aPRP- and FBS-containing media did not express hematopoietic markers, such as CD14, CD34 and CD45, or HLA-DR, while they expressed stromal cell markers such as CD13, CD44, CD73, CD90, CD105, and CD106. These results completely agreed with other studies of UCB-MSCs cultured in FBS-supplemented medium [8,9,59-61], human peripheral blood-derived PRP [62], and UCB-derived PRP [49-51]. UCB-MSCs cultured in the various media also exhibited multilineage differentiation to adipocytes, osteoblasts, and chondrocytes. These results were similar to those of UCB-MSCs isolated in serum-supplemented medium [8,9,59-61].

Some previous studies have shown that PRP has some effects on MSCs. In addition to PRP strongly stimulating MSC proliferation, PRP also triggers differentiation. However, these effects of PRP are different between the various types of MSCs. PRP induces UCB-MSCs and bone marrow-derived MSCs to differentiate into osteoblasts [46], [53,63] and adipose-derived stem cells to differentiate into chondrocytes [7]. In this study, we did not evaluate the effects of PRP on UCB-MSC differentiation. However, we found that MSCs cultured in medium containing 2, 5, 7, or 10% aPRP maintained their potential for differentiation into adipocytes, osteoblasts, and chondrocytes. This result indicated that aPRP cultured UCB-MSCs had not become mature cells such as osteoblasts or chondrocytes. In fact, in previous studies, although MSCs have been proposed to differentiate into osteoblasts and chondrocytes, they also maintain their differentiation capacity for adipocytes, osteoblasts, and chondrocytes [62,64]. In our final analysis, UCB-MSCs cultured in the various media were examined for tumorigenicity in athymic nude mice. The results showed that all mice injected with UCB-MSCs cultured in the various media showed no tumor formation at the injection site, while cancer cells caused tumor formation in all mice at their injection site.

In summary, we successfully established a protocol for isolation of GMP-compliant UCB-MSCs. For primary culture, IMDM plus 10% aPRP is appropriate. For expansion, culture medium plus 5% aPRP is suitable. This protocol complies with GMP because of its xenogenic- and allogeneic-free medium components.

**Conclusion**

UCB is a rich source of MSCs. UCB-MSCs can be isolated with xenogenic and allogeneic component-free medium. In this study, we successfully established a GMP-compliant UCB-MSC isolation protocol. Autologous aPRP can be used to replace FBS. Both aPRP and MNCs can be isolated from the same blood sample. In primary culture, MNCs should be cultured in IMDM plus 10% aPRP and 1% antibiotic-mycotic. However, in expansion culture, MSCs should be cultured in IMDM plus 5% aPRP and 1% antibiotic-mycotic. MSCs isolated by this protocol proliferate similarly as those in 10% FBS, maintain MSC phenotypes such as expression of CD13, CD44, CD73, CD90, CD105, CD106, and CD166, and do not express CD14, CD34, CD45, or HLA-DR. They also maintain their multilineage differentiation potential for adipocytes, osteoblast, and chondrocytes. In particular, the isolated MSCs do not form tumors at a high dose in athymic nude mice. This promising protocol is suitable for clinical applications of UCB-MSCs in the near future.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

PVP, NBV conceived the study, performed PRP preparation, evaluated the effects of PRP on mesenchymal stem cell proliferation. VMP, NHT primarily cultured mesenchymal stem cells from mononuclear cells; TLBP, TTN collected umbilical cord blood, isolated mononuclear cells from umbilical cord blood, performed PRP preparation.
cord blood, LTDD, ANTB carried out the differentiation assays; NK evaluated the tumorigenicity of MSCs in mice model. All authors read and approved the final manuscript.

Acknowledgements

This work was funded by grants from Vietnam National University, Ho Chi Minh city, Vietnam.

Received: 6 November 2013 Accepted: 19 February 2014
Published: 24 February 2014

References

1. Friedenstein AJ, Patelctzy S II, Petakova KV: Osteogenesis in transplants of bone marrow cells. J Entody Exp Morphol 1966, 16:381–390.
2. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, Rudlkaova IA: Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol' 1974, 283–92.
3. Prokop DJ, Sekiya I, Colter DC: Isolation and characterization of rapidly self-renewing stem cells from cultures of human marrow stromal cells. Cytotherapy 2001, 3:393–396.
4. Jones EA, Kinsey SE, English A, Jones RA, Staszynski L, Meredith DM, Markham AF, Jack A, Emery P, McConigal D: Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 2002, 46:3349–3360.
5. Bunnell BA, Flatt M, Gagliardi C, Patel B, Ripoll C: Adipose-derived stem cells: Isolation, expansion and differentiation. Methods 2008, 48:115–120.
6. Boquest AC, Shafidzadfar A, Brinchmann JE, Collas P: Isolation of stem cells from human adipose tissue. Methods Mol Biol 2006, 325:35–46.
7. Van Pham P, Bui KH, Ngo DQ, Vu NB, Truong NH, Phan NL, Le DM, Duong TD, Nguyen TD, Le VT, Phan NK: Activated platelet-rich plasma improves adipose-derived stem cell transplantation efficacy in injured articular cartilage. Stem Cell Res Ther 2013, 4:61.
8. Bieback K, Kern S, Kluter H, Eckhard H: Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004, 22:625–634.
9. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH: Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004, 103:1669–1675.
10. Mareschi K, Basini E, Paciello W, Aglietta M, Madon E, Fagiolli F: Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. Haematologica 2001, 86:1099–1100.
11. Phuc PV, Nhung TH, Loan DT, Chung DC, Ngoc PK: Differentiating of banked human umbilical cord blood-derived mesenchymal stem cells into insulin-secreting cells. In vitro Cell Dev Biol Anim 2011, 47:54–60.
12. Phuc PV, Ngoc VB, Lam DH, Tam NT, Van PQ, Ngoc PK: Isolation of three important types of stem cells from the same samples of banked umbilical cord blood. Cell Tissue Bank 2012, 13:341–351.
13. Gong W, Han Z, Zhao H, Wang Y, Wang J, Zhong J, Wang B, Wang S, Wang Y, Sun L, Han Z: Banking human umbilical cord-derived mesenchymal stromal cells for clinical use. Cell Transplant 2012, 21:207–216.
14. Matsuo A, Yamaoka Y, Takase C, Ayagi K, Uchinuma E: Osteogenic potential of cryopreserved human bone marrow-derived mesenchymal stem cells cultured with autologous serum. J Craniol Surg 2008, 19:693–700.
15. Romonov YA, Svirolskaya VA, Smirnov VN: Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells 2003, 21:105–110.
16. Wang HS, Huang SC, Peng ST, Huang CC, Wei HM, Guo YJ, Fu YS, Lai MC, Chen CC: Mesenchymal stem cells in the Wharton's jelly of the umbilical cord. Stem Cells Dev 2004, 2013:1300–1307.
17. In’t Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, Fanhai HH: Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004, 22:1383–1385.
18. Roubelakis MG, Pappa KI, Bitsika V, Zagoura D, Vlahos A, Papadaki HA, Antsaklis A, Anagnostou NP: Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev 2007, 16:891–952.
19. Perry BC, Zhou D, Wu X, Yang FC, Byers MA, Chu TM, Hockema JI, Woods EE, Goebel WS: Collection, cryopreservation, and characterization of human dental pulp-derived mesenchymal stem cells for banking and clinical use. Tissue Eng Part C Methods 2008, 14:149–156.
20. Ulrich D, Muratlihan R, Gargett CE: Toward the use of endometrial and menstrual blood mesenchymal stem cells for cell-based therapies. Expert Opin Biol Ther 2013, 13:1387–1400.
21. Verina T, Fatemi A, Johnston MV, Comi AM: Pluripotent possibilities: human umbilical cord blood cell treatment after neonatal brain injury. Pediatr Neurol 2013, 48:346–354.
22. Chung WH, Park SA, Lee JH, Chung DJ, Choi CB, Kim DH, Han H, Kim HY: Percutaneous transplantation of human umbilical cord-derived mesenchymal stem cells in a dog with suspected fibrocartilaginous embolic myelopathy. J Vet Sci 2013, 14:495–497.
23. Lee JH, Chang HS, Kang EH, Chung DJ, Choi CB, Lee JH, Hwang SH, Han H, Kim HY: Percutaneous transplantation of human umbilical cord blood-derived multipotent stem cells in a canine model of spinal cord injury. J Neurosurg Spine 2009, 11:749–757.
24. Roh DH, Seo MS, Choi HS, Park SB, Han HJ, Beitz AJ, Kang KS, Lee JH: Transplantation of human umbilical cord blood or amniotic epithelial stem cells alleviates mechanical allodynia after spinal cord injury in rats. Cell Transplant 2013, 22:1577–1590.
25. Park JH, Hwang I, Hwang SH, Han H, Ha H: Human umbilical cord blood-derived mesenchymal stem cells prevent diabetic renal injury through paracrine action. Diabetes Res Clin Pract 2012, 98:465–473.
26. Park JH, Park J, Hwang SH, Han H, Ha H: Delayed treatment with human umbilical cord-blood-derived stem cells attenuates diabetic renal injury. Transplant Proc 2012, 44:123–1126.
27. An JH, Park H, Song JA, Ki KH, Yang JY, Choi HJ, Cho SW, Kim SW, Kim SY, Yoo JJ, Baek WY, Kim JE, Choi SJ, Oh WH, Shin CS: Transplantation of human umbilical cord blood-derived mesenchymal stem cells or their conditioned medium prevents bone loss in ovariectomized nude mice. Tissue Eng Part A 2013, 19:685–696.
28. Roura S, Bago JR, Soler-Botija C, Pujal JM, Galvez-Monturon C, Prat-Vidal C, Lucía-Valdepeñas A, Blanco J, Reyes-Genis A: Human umbilical cord blood-derived mesenchymal stem cells promote vascular growth in vivo. PLoS One 2012, 7:e49447.
29. Lim YJ, Jeong CH, Jun JA, Kim SM, Ryu CH, Huh Y, Oh W, Chang JW, Iun SS: Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia. Stem Cell Res Ther 2011, 2:18.
30. Choi MY, Yeo SW, Park KH: Hearing restoration in a deaf animal model with intravenous transplantation of mesenchymal stem cells derived from human umbilical cord blood. Biochem Biophys Res Commun 2012, 427:629–636.
31. Joyce NC, Harris DL, Markov V, Zhang Z, Saitta B: Potential of human umbilical cord blood mesenchymal stem cells to heal damaged corneal endothelium. Mol Vis 2012, 18:547–564.
32. Kim JY, Kim DH, Lee J, Jeon HB, Kwon SJ, Kim SM, Yoo YJ, Baek WY, Kim JE, Choi SJ, Oh WH, Shin CS: Transplantation of human umbilical cord blood-derived mesenchymal stem cells or their conditioned medium prevents bone loss in ovariectomized nude mice. Tissue Eng Part A 2013, 19:685–696.
33. Gregoire-Gauthier J, Selleri S, Fontaine F, Dieng MM, Patey N, Despars G, Beaurejour CM, Haddad E: Therapeutic efficacy of cord blood-derived mesenchymal stromal cells to heal damaged corneal endothelium. Mol Vis 2012, 18:547–564.
34. Shi LL, Liu FP, Wang DW: Transplantation of human umbilical cord blood mesenchymal stem cells improves survival rates in a rat model of acute hepatic necrosis. Am J Med Sci 2011, 342:212–217.
35. Ngoc PK, Phuc PV, Nhung TH, Thuy DT, Nguyen NT: Improving the efficacy of type 1 diabetes therapy by transplantation of immunosolated insulin-producing cells. Hum Cell 2011, 24:865–870.
36. Jung KH, Uhm YK, Lim YJ, Yim SY: Human umbilical cord blood-derived mesenchymal stem cells improve glucose homeostasis in rats with liver cirrhosis. Int J Oncol 2011, 39:137–143.
37. Ly VT, Zhang Y, Liu M, Quwaxji JN, Ashwood P, Cho SC, Huan Y, Ge RC, Chen XW, Wang ZJ, Kim BJ, Hu X: Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Transl Med 2013, 11:196.
38. Jin JL, Liu Z, Lu ZL, Guan DN, Wang C, Chen ZB, Zhang J, Zhang WY, Wu YJ, Xu Y: Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spinocerebellar ataxia. Curr Neurovasc Res 2013, 10:11–20.

39. Li XY, Zheng ZH, Li XY, Guo J, Zhang Y, Li H, Wang YW, Ren J, Wu ZB: Treatment of foot disease in patients with type 2 diabetes mellitus using human umbilical cord blood mesenchymal stem cell response and correction of immunological anomalies. Curr Pharm Des 2013, 19:4893–4899.

40. Han H, Chang SK, Chang JJ, Hwang SH, Han SH, Chun BH: Intrathelial injection of human umbilical cord blood-derived mesenchymal stem cells for the treatment of basal artery dissection: a case report. J Med Case Rep 2011, 5:562.

41. Dazezy B, Ducheze P, Leetelie C, Vezon G, Ivanovic Z: Cord blood processing by using a standard manual technique and automated closed system “Sepax” (Kit CS-330). Stem Cells Dev 2005, 14:6–10.

42. Selves P, Planellese D, Mirabet V, Blanquer A, Carbonell-Uberos F: Qualitative and quantitative cell recovery in umbilical cord blood processed by two automated devices in routine cord blood banking: a comparative study. Blood Transfus 2013, 11:405–411.

43. Aktas M, Buchheiser A, Houben A, Reimann V, Radke T, Jeltsch K, Maier P, Zeller WJ, Kogler G: Good manufacturing practice-grade production of unrestricted somatic stem cell from fresh cord blood. Cytotherapy 2010, 12:338–348.

44. Kocaomer A, Kern S, Kluter H, Bieback K: Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007, 25:1270–1278.

45. Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, Strunk D, Kluter H: Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009, 27:2331–2341.

46. Jonsdottir-Buch SM, Lieder R, Sigurjonsson OE: Platelet lysates produced from expired platelet concentrates support growth and osteogenic differentiation of mesenchymal stem cells. PLoS One 2013, 8:e69884.

47. Rauch C, Fiefer E, Aumann EM, Spott HP, Schnennich H, Pfaller W, Gstraunthaler G: Alternatives to the use of fetal bovine serum: human platelet lysate serum display higher self-renewal and enhanced osteogenic potential. Stem Cells Dev 2009, 18:359–371.

48. Blande IS, Bassaneze V, Lavini-Ramos C, Fae KC, Kalil J, Miyakawa AA, Forte G, Moreno I, Lezameta M, Ayuso-Sacido A, Garcia-Verdugo JM: Human AB serum and thrombin-activated platelet lysates as a serum substitute in cell culture media. BioMed Res Int 2011, 2011:316.

49. Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, Strunk D, Kluter H: Intermediate effects of human umbilical cord-derived MSC culture: the replacement of animal sera with human cord blood plasma. In Vitro Cell Dev Biol Anim 2013, 49:100–107.

50. Shetty P, Bharucha K, Tanavde V: Human umbilical cord blood serum can replace fetal bovine serum in the culture of mesenchymal stem cells. Cell Biol Int 2007, 31:293–298.

51. Ma HY, Yao L, Yu YQ, Li L, Ma L, Wei WJ, Lu XM, Du LL, Jin YN: An effective and safe supplement for stem cells expansion ex vivo: cord blood serum. Cell Transplant 2012, 21:857–869.

52. Murphy MB, Blashki D, Buchanan RM, Yazdi IK, Ferrari M, Simmons PJ, Tascotti E: Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryopreservation. Biomaterials 2012, 33:5308–5316.

53. Baba K, Yamazaki Y, Ishiguro M, Kumazawa K, Aoyagi K, Ikemoto S, Takeda A, Uchiuma E: Osteogenic potential of human umbilical cord-derived mesenchymal stem cells cultured with human umbilical cord-derived fibrin: A preliminary study. J Cranio-maxillofac Surg 2013, 41(8):775–782.

54. Escobedo-Lucea C, Bellver C, Gandia C, Sanz-Garcia A, Esteban FJ, Mirabet V, Forte G, Moreno I, Lezameta M, Ayuso-Sacido A, Garcia-Verdugo JM: A xenogeneic-free protocol for isolation and expansion of human adipose stem cells for clinical uses. PLoS One 2013, 8:e67870.

55. Fekete N, Rojewski MT, Furst D, Kreja J, Ignatius A, Dauendorf S, Schrezenmeier H: GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS One 2012, 7:e32555.

56. Marx RE: Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004, 62:489–496.

57. Lee JY, Nam H, Park YJ, Lee SJ, Chung CP, Han SB, Lee G: The effects of platelet-rich plasma derived from human umbilical cord blood on the osteogenic differentiation of human dental stem cells. In Vitro Cell Dev Biol Anim 2011, 47:157–164.

58. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8:315–317.

59. Hua J, Gong J, Meng H, Xu B, Yao L, Qian M, He Z, Zou S, Zhou B, Song Z: Comparison of different methods for the isolation of mesenchymal stem cells from umbilical cord blood and bone marrow. Cell Biol Int 2013. [Epub ahead of print].

60. Lee MK, Yang MS, Park JS, Kim HC, Kim YJ, Choi J: Isolation of mesenchymal stem cells from cryopreserved human umbilical cord blood. Int J Hematol 2005, 81:126–130.

61. Laitinen A, Laine J: Isolation of mesenchymal stem cells from human cord blood. Curr Protoc Stem Cell Biol 2007, Chapter 2:Unit 2A 3.

62. Prins HJ, Rozemuller H, Vonk-Griffioen S, Verweij VG, Dhert WJ, Slaper-Cortenbach IC, Martens AC: Bone-forming capacity of mesenchymal stromal cells when cultured in the presence of human platelet lysate as substitute for fetal bovine serum. Tissue Eng Part A 2009, 15:3741–3751.

63. Jung J, Moon N, Ahn YJ, Oh EJ, Kim M, Cho CS, Shin JC, Oh IH: Mesenchymal stromal cells expanded in human allogeneic cord blood serum display higher self-renewal and enhanced osteogenic potential. Stem Cells Dev 2009, 18:559–571.

64. Vogel JP, Salay K, Geiger F, Kramer M, Richter W, Kasten P: Platelet-rich plasma improves expansion of human mesenchymal stem cells and retains differentiation capacity and in vivo bone formation in calcium phosphate ceramics. Platelets 2006, 17:462–469.